Validity of at-home rapid antigen lateral flow assay and artificial intelligence read to detect SARS-CoV-2.
Diagn Microbiol Infect Dis
; 104(3): 115763, 2022 Nov.
Article
in English
| MEDLINE | ID: covidwho-1914300
ABSTRACT
BACKGROUND:
The gold standard for COVID-19 diagnosis-reverse-transcriptase polymerase chain reaction (RT-PCR)- is expensive and often slow to yield results whereas lateral flow tests can lack sensitivity.METHODS:
We tested a rapid, lateral flow antigen (LFA) assay with artificial intelligence read (LFAIR) in subjects from COVID-19 treatment trials (N = 37; daily tests for 5 days) and from a population-based study (N = 88; single test). LFAIR was compared to RT-PCR from same-day samples.RESULTS:
Using each participant's first sample, LFAIR showed 86.2% sensitivity (95% CI 73.6%-98.8) and 94.3% specificity (88.8%-99.7%) compared to RT-PCR. Adjusting for days since symptom onset and repeat testing, sensitivity was 97.8% (89.9%-99.5%) on the first symptomatic day and decreased with each additional day. Sensitivity improved with artificial intelligence (AI) read (86.2%) compared to the human eye (71.4%).CONCLUSION:
LFAIR showed improved accuracy compared to LFA alone. particularly early in infection.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Artificial Intelligence
/
COVID-19 Serological Testing
/
SARS-CoV-2
/
COVID-19
/
Antigens, Viral
Type of study:
Diagnostic study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Diagn Microbiol Infect Dis
Year:
2022
Document Type:
Article
Affiliation country:
J.diagmicrobio.2022.115763
Similar
MEDLINE
...
LILACS
LIS